Newly Diagnosed CML: Addressing Secondary Resistance

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: August 02, 2013
Expiration Date: August 02, 2014

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this educational activity, Dr. Jerald Radich will address secondary resistance to primary therapy in the treatment of newly diagnosed chronic myeloid leukemia (CML) through appropriate monitoring, mutation analysis, and alternative TKI selection based on these analyses. Methods for reducing treatment-related toxicities will also be addressed.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and nurses, and other health care professionals who have an interest in enhancing their clinical skills in CML.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Compare and contrast monitoring recommendations by the NCCN and ELN for CML
  • Recall the appropriate timing of mutational analysis
  • Relate considerations in the selection of alternative TKI therapy based on mutation analysis results and methods to reduce treatment-related toxicities

Agenda

Newly Diagnosed CML: Addressing Secondary Resistance – Jerald P. Radich, MD

Instructions for Participation and Credit

This activity is eligible for credit through August 2, 2014. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biography

Jerald P. Radich, MD
Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor of Medicine
University of Washington
Seattle, Washington

Dr. Jerald Radich is a member of the clinical research division at the Fred Hutchinson Cancer Research Center (FHCRC) and is professor of medicine at the University of Washington. He is the medical director of the research trials office at the FHCRC, the co-chair of leukemia biology for the Southwest Oncology Group, and is the co-chair of the NCI/Cooperative Group Leukemia Steering Committee. He belongs to the National Cancer Care Network and EuroLeukemiaNet CML committees. Dr. Radich's main research interest concerns the genetics of leukemia, and the use and development of modern molecular biology techniques to further early detection of leukemia.

Accreditation

CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-13-365-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.

NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 13-365-329

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Jerald Radich has received honoraria as a consultant from Novartis Corporation, Bristol-Myers-Squibb, ARIAD Pharmaceuticals, Inc., Incyte Corporation and Amgen, Inc..

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Radich has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Radich has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@managingcml.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Teva Pharmaceuticals and Novartis Corporation.

©2013 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.